Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin
Streams: Advanced Therapies, Biomedical Engineering, Cancer
Ali Ardakani is a technical and entrepreneurial corporate development and operations biotech executive with 20 years of experience in managing life science projects and companies. His experience includes managing R&D projects in the areas of oncology, respiratory, infectious disease, CNS therapeutics and medical devices, as well as fundraising, licensing and M&A.
Ali is the Founder & Managing Director of Novateur Ventures. Until recently he was Senior Vice President Device & Business Development for Beyond Air (NASDAQ:XAIR), where he was involved with the company from early stage until Nasdaq public offering and several rounds of financing and licensing. He is the CEO and co-founder of Optigo Biotherapeutics, an ophthalmology R&D company, the Chair of LifeSciences BC. He is also an Associate at Creative Destruction Labs.
To date, Ali has taken several projects from concept to FDA approval, including several 510(k)s, PMA for medical devices and several FDA INDs. He has also worked on commercialization and pharma partnerships, as well as several global mergers and acquisitions.